研究者詳細 - 國定　俊之

論文 - 國定　俊之

分割表示 556 件中 381 - 400 件目／全件表示 >>

ゾレドロン酸とテロメラーゼ依存性腫瘍融解アデノウイルスの併用療法は骨肉腫に対する抗腫瘍効果を増強し、骨破壊を抑制する

山川泰明, 長谷井嬢, 田澤大, 杉生和久, 魚谷弘二, 尾崎修平, 吉田晶, 藤原智洋, 武田健, 国定俊之, 浦田泰生, 藤原俊義, 尾崎敏文

日本整形外科学会雑誌 89 ( 6 ) S1244 - S1244 2015年6月

悪性骨盤骨腫瘍術後リハビリテーション一時的創外固定法の有用性

国定俊之, 武田健, 藤原智洋, 野田知之, 堅山佳美, 千田益生, 尾崎敏文

日本整形外科学会雑誌 89 ( 6 ) S1197 - S1197 2015年6月

滑膜肉腫における患者血清由来分泌型miRNAの特定

吉田晶, 藤原智洋, 魚谷弘二, 山川泰明, 大森敏規, 杉生和久, 武田健, 国定俊之, 根津悠, 川井章, 落谷孝広, 尾崎敏文

日本整形外科学会雑誌 89 ( 6 ) S1228 - S1228 2015年6月

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study 査読

Akira Kawai, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Mitsuru Takahashi, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Takanori Tanase, Tadashi Hasegawa, Shunji Takahashi

LANCET ONCOLOGY 16 ( 4 ) 406 - 416 2015年4月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：ELSEVIER SCIENCE INC

Background Trabectedin binds to the minor groove of DNA and blocks DNA repair machinery. Preclinical data have shown that trabectedin also modulates the transcription of the oncogenic fusion proteins of translocation-related sarcomas. We aimed to assess the efficacy and safety of trabectedin as second-line therapy or later for patients with advanced translocation-related sarcoma.
Methods We did a multicentre randomised open-label study in Japan. Eligible patients had pathological diagnosis of translocation-related sarcoma, were aged 19 years or older, were unresponsive or intolerant to standard chemotherapy regimens, no more than four previous chemotherapy regimens, Eastern Cooperative Oncology Group performance status 0 or 1, adequate bone marrow reserve, renal and liver functions, and had measurable lesions. Patients were randomly assigned (1: 1) by the minimisation method to receive either trabectedin (1.2 mg/m(2) given via a central venous line over 24 h on day 1 of a 21 day treatment cycle) or best supportive care, which was adjusted centrally by pathological subtype. Investigators, patients, and the sponsor were unmasked to the treatment assignment. Progression-free survival and objective responses were assessed by a masked central radiology imaging review. Efficacy was assessed by masked central radiology imaging review. The primary endpoint was progression-free survival for the full analysis set population. Follow-up is ongoing for the patients under study treatment. The study is registered with Japan Pharmaceutical Information Center, number JapicCTI-121850.
Findings Between July 11, 2012, and Jan 20, 2014, 76 patients were enrolled and allocated to receive either trabectedin (n= 39) or best supportive care (n= 37). After central review to confirm pathological subtypes, 73 patients (37 in the trabectedin group and 36 in the best supportive care group) were included in the primary efficacy analysis. Median progression-free survival of the trabectedin group was 5.6 months (95% CI 4.1-7.5) and the best supportive care group was 0.9 months (0.7-1.0). The hazard ratio (HR) for progression-free survival of trabectedin versus best supportive care was 0.07 (90% CI 0.03-0.14 and 95% CI 0.03-0.16) by a Cox proportional hazards model (p< 0.0001). The most common drug-related adverse events for patients treated with trabectedin were nausea (32 [89%] of 36), decreased appetite (21 [58%]), decreased neutrophil count (30 [83%]), increased alanine aminotransferase (24 [67%]), and decreased white blood cell count (20 [56%]).
Interpretation Trabectedin significantly reduced the risk of disease progression and death in patients with advanced translocation-related sarcoma after standard chemotherapy such as doxorubicin, and should be considered as a new therapeutic treatment option for this patient population.

DOI： 10.1016/S1470-2045(15)70098-7

藤原智洋, 武田健, 国定俊之, 尾崎敏文

中国・四国整形外科学会雑誌 27 ( 1 ) 224 - 224 2015年4月

【骨腫瘍の診断と治療】化学療法 Ewing肉腫に対する化学療法

武田健, 藤原智洋, 国定俊之, 尾崎敏文

関節外科 34 ( 4 ) 338 - 343 2015年4月

骨軟部腫瘍における画像評価最前線シンチグラフィを用いた骨軟部腫瘍の機能的画像診断

国定俊之, 武田健, 藤原智洋, 上原健敬, 大森敏規, 尾崎敏文

臨床整形外科 50 ( 3 ) 229 - 235 2015年3月

記述言語：日本語出版者・発行元：(株)医学書院

骨軟部腫瘍の診断・治療では,骨シンチグラフィ,タリウムシンチグラフィが有用な画像診断法である.骨シンチグラフィは,骨腫瘍の活動性が評価可能であり,単発性・多発性発生の診断や悪性骨腫瘍では骨転移の診断に役立つ.タリウムシンチグラフィは腫瘍の活動性や悪性度を反映するため,術前治療の効果判定や良性・悪性の鑑別診断に有用である.術前治療が有効と判定可能であれば,縮小手術が可能となりうる.タリウムシンチグラフィとDMSAシンチグラフィを行うことで,軟骨系骨腫瘍の悪性度診断も可能とある.画像診断で良性・悪性の鑑別ができれば,外来診療での治療方針決定の一つの指標となる.(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J01554&link_issn=&doc_id=20150304050011&doc_link_id=10.11477%2Fmf.1408200144&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1408200144&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

骨温存のため液体窒素処理骨と腫瘍用人工関節術を併用した2例

上原健敬, 国定俊之, 大森敏規, 藤原智洋, 武田健, 尾崎敏文

中部日本整形外科災害外科学会雑誌 58 ( 春季学会 ) 224 - 224 2015年3月